Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease

Trial Profile

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs RO 6924963 (Primary) ; RO 6931643 (Primary) ; RO 6958948 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2016 Status changed from active, no longer recruiting to completed.
    • 02 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top